Haowen Ran

Haowen Ran

Auto-generated profile, based on publicly available information

Haowen Ran

Nanhu Laboratory, National Center of Biomedical Analysis, Beijing, China. 1

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
XZXiaoyan Zhan
Xiaoyan Zhan
SGSaisai Guo
Saisai Guo
YLYuanyuan Li
Yuanyuan Li
HRHaowen Ran
Haowen Ran
HHHaohao Huang
Haohao Huang
JMJianghong Man
Jianghong Man
Type I interferons (IFNs) are known to mediate antineoplastic effects during tumor progression. Type I IFNs can be produced by multiple cell types in the tumor microenvironment; however, the molecular mechanisms by which tumor cells evade the inhibition of immune microenvironment remain unknown. Here we demonstrate that glioma stem-like cells (GSCs) evade type I IFN suppression through downregulation of STAT1 to initiate tumor growth under inhospitable conditions. The downregulation of STAT1 is mediated by MBD3, an epigenetic regulator. MBD3 is preferentially expressed in GSCs and recruits NuRD complex to STAT1 promoter to suppress STAT1 expression by histone deacetylation. Importantly, STAT1 overexpression or MBD3 depletion induces p21 transcription, resensitizes GSCs to IFN suppression, attenuates GSC tumor growth, and prolongs animal survival. Our findings demonstrate that inactivation of STAT1 signaling by MBD3/NuRD provides GSCs with a survival advantage to escape type I IFN suppression, suggesting that targeting MBD3 may represent a promising therapeutic opportunity to compromise GSC tumorigenic potential.

1 April 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
LCLishu Chen
Lishu Chen
QQQinghui Qi
Qinghui Qi
XJXiaoqing Jiang
Xiaoqing Jiang
JWJin Wu
Jin Wu
YLYuanyuan Li
Yuanyuan Li
JMJianghong Man
Jianghong Man
Glioblastoma (GBM) exhibits profound metabolic plasticity for survival and therapeutic resistance, while the underlying mechanisms remain unclear. Here, we show that GBM stem cells reprogram the epigenetic landscape by producing substantial amounts of phosphocreatine (PCr). This production is attributed to the elevated transcription of brain-type creatine kinase, mediated by Zinc finger E-box binding homeobox 1. PCr inhibits the poly-ubiquitination of the chromatin regulator bromodomain containing protein 2 (BRD2) by outcompeting the E3 ubiquitin ligase SPOP for BRD2 binding. Pharmacological disruption of PCr biosynthesis by cyclocreatine (cCr) leads to BRD2 degradation and a decrease in its targets’ transcription, which inhibits chromosome segregation and cell proliferation. Notably, cyclocreatine treatment significantly impedes tumor growth and sensitizes tumors to a BRD2 inhibitor in mouse GBM models without detectable side effects. These findings highlight that high production of PCr is a druggable metabolic feature of GBM and a promising therapeutic target for GBM treatment. Significance: Glioblastoma (GBM) exhibits an adaptable metabolism crucial for survival and therapy resistance. We demonstrate that GBM stem cells modify their epigenetics by producing phosphocreatine (PCr), which prevents bromodomain containing protein 2 (BRD2) degradation and promotes accurate chromosome segregation. Disrupting PCr biosynthesis impedes tumor growth and improves the efficacy of BRD2 inhibitors in mouse GBM models.

2 January 2025
Verified
Other
Open access
LCLishu Chen
Lishu Chen
QQQinghui Qi
Qinghui Qi
XJXiaoqing Jiang
Xiaoqing Jiang
JWJin Wu
Jin Wu
YLYuanyuan Li
Yuanyuan Li
JMJianghong Man
Jianghong Man
Supplementary Table S2 shows CKB IHC staining score in human glioma microarray.

17 June 2026
Verified
Other
Open access
PDF file
LCLishu Chen
Lishu Chen
QQQinghui Qi
Qinghui Qi
XJXiaoqing Jiang
Xiaoqing Jiang
JWJin Wu
Jin Wu
YLYuanyuan Li
Yuanyuan Li
JMJianghong Man
Jianghong Man
Supplementary Table S3 shows UCSC-predicted transcription factors that bind to CKB promoters.

23 January 2025
Verified
Other
Open access
LCLishu Chen
Lishu Chen
QQQinghui Qi
Qinghui Qi
XJXiaoqing Jiang
Xiaoqing Jiang
JWJin Wu
Jin Wu
YLYuanyuan Li
Yuanyuan Li
JMJianghong Man
Jianghong Man
Supplementary Table S5 shows the detailed genetic mutations of four GBM cell lines.

23 January 2025
Verified
Other
Open access
PDF file
LCLishu Chen
Lishu Chen
QQQinghui Qi
Qinghui Qi
XJXiaoqing Jiang
Xiaoqing Jiang
JWJin Wu
Jin Wu
YLYuanyuan Li
Yuanyuan Li
JMJianghong Man
Jianghong Man
Supplementary Table S7 shows the primer sequences used for Real-Time PCR.